Sana Announces Upsized Pricing of Initial Public Offering
SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of its upsized initial public offering of 23,500,000 shares of its common stock at a public offering price of $25.00 per share. All of the shares of common stock are being offered by Sana. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Sana, are expected to be $587.5 million. Sana’s common stock is expected to begin trading on The Nasdaq Global Select Market on February 4, 2021, under the ticker symbol “SANA.” The offering is expected to close on February 8, 2021, subject to the satisfaction of customary closing conditions. In addition, Sana has granted the underwriters a 30-day option to purchase up to an additional 3,525,000 shares of common s
Press release content from PR Newswire. The AP news staff was not involved in its creation.
“Nine Actionable Solutions to Reimagining Board Diversity”
January 25, 2021 GMT
Ellig Group is a leader in recruiting and onboarding executive talent, with highly diverse backgrounds and experiences, and helping organizations identify exceptional leaders for their evolving needs. We are reimagining search by providing an expanded platform of services including a holistic approach to talent identification and development through our Executive/Board advisory and assessment capabilities, AI/analytics, as well as our leadership development and onboard programs. elliggroup.com (PRNewsfoto/Ellig Group)
Ellig Group is a leader in recruiting and onboarding executive talent, with highly diverse backgrounds and experiences, and helping organizations identify exceptional leaders for their evolving needs. We are reimagining search by providing an expanded platform of services including a holistic
Sana Biotechnology went public before testing any treatments in people.
The cell and gene therapy startup won t launch clinical trials for at least a year.
Noted life sciences VCs Flagship Pioneering and Arch Venture Partners were its biggest shareholders pre-IPO.
Cell and gene editing startup Sana Biotechnology s shares jumped more than 40% on its first day of trading, making one of its investors stakes worth more than $1.5 billion.
The company sold 23.5 million shares at $25 apiece Thursday. Its stock price was up 40.40% at the end of the first day of trading, closing at $35.10 per share. Sana will have about 185 millions shares outstanding after the IPO, valuing the company at $6.5 billion.
The start of a new year is a good time to take stock of where the digital health industry stands. From just-budding startups to newly minted unicorns to publicly traded players, it s seeming like 2021 will be a critical year for the sector as the pandemic (hopefully) starts to ebb.
On the early-stage side, Megan spoke with Lynne Chou O Keefe, the founder of Define Ventures, about the firm s latest $200 million fund.
One type of startup to keep an eye out for in 2021: companies that sound a lot like Livongo.
Startups, billionaire investor Vinod Khosla said at a Startup Health chat on Tuesday, should be wary of working with entrenched players. While talking about the work that BioNTech did with Pfizer to speed up the development and distribution of COVID-19 vaccines, Khosla said that collaboration is generally BS–with some exceptions.
Advertisement
Startups, billionaire investor Vinod Khosla said at a Startup Health chat on Tuesday, should be wary of working with entrenched players. While talking about the work that BioNTech did with Pfizer to speed up the development and distribution of COVID-19 vaccines, Khosla said that collaboration is generally BS-with some exceptions.
Read his full explanation as to why here
As some digital health startups get bigger, it s been interesting to see how their strategies evolve.
Advertisement
Megan spoke with $1.5 billion digital-health startup Ro about its goal to to be your online doctor.
Also on the bigger end of digital health, Hugh Langley and Blake rounded up all the departures from Alphabet s life sciences arm Verily in the last year.